Skip to main content

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Trial Status: Closed to Accrual

The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.

Inclusion Criteria

  • Be 18 years of age at the time the informed consent form is signed
  • Have a histologically confirmed diagnosis of high-grade serous or Grade 2 or Grade 3 endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer
  • Received ≥ 2 prior chemotherapy regimens and have relapsed or progressive disease as confirmed by radiologic assessment
  • Have biopsiable and evaluable disease. Note: biopsy is optional for patients known to harbor a BRCA1/2 mutation
  • Have sufficient archival formalin-fixed paraffin-embedded (FFPE) tumor tissue available for planned analyses

Exclusion Criteria

  • History of prior cancers except for those that have been curatively treated, with no evidence of cancer currently (provided all chemotherapy was completed >6 months prior and/or bone marrow transplant >2 years prior to first dose of rucaparib).
  • Prior treatment with any PARP inhibitor
  • Symptomatic and/or untreated central nervous system metastases
  • Pre-existing duodenal stent and/or any other gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparib
  • Women who are pregnant or breast feeding
  • Hospitalization for bowel obstruction within 3 months prior to enrollment


UC Irvine Health / Chao Family Comprehensive Cancer Center
San Francisco
UCSF Medical Center-Mount Zion


Wayne State University / Karmanos Cancer Institute


Fred Hutch / University of Washington Cancer Consortium

Rucaparib is an orally available, small molecule inhibitor of poly-adenosine diphosphate

[ADP] ribose polymerase (PARP) being developed for treatment of ovarian cancer associated

with homologous recombination (HR) DNA repair deficiency (HRD). The safety and efficacy of

rucaparib has been evaluated in several Phase 1 and Phase 2 studies. An oral formulation is

the focus of current development efforts. Rucaparib is currently being investigated as

monotherapy in patients with cancer associated with breast cancer susceptibility gene 1

(BRCA1) or BRCA2 mutations.

While PARP inhibitors have demonstrated consistent robust clinical activity in patients with

relapsed ovarian cancer associated with HRD, prospective studies evaluating efficacy and

safety of PARPi versus standard of care chemotherapy have been limited. The primary purpose

of this Phase 3 study is to compare the efficacy and safety of rucaparib versus chemotherapy

as treatment for relapsed ovarian cancer in patients with a deleterious BRCA1/2 mutation in

their tumor.

Trial Phase Phase III

Trial Type Treatment

Lead Organization
Clovis Oncology

  • Primary ID CO-338-043
  • Secondary IDs NCI-2016-01669
  • ID NCT02855944